search
Back to results

Integrating ePReBMs From Phoenix in Respiratory Diseases

Primary Purpose

Pulmonary Hypertension, COPD, Interstitial Lung Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Health Gauge AI-Based Wearable Device - Model: Phoenix
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Pulmonary Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Male or female volunteers, at least 18 years of age at the time of screening visit; Fluent in English and able to follow the instructions to use the Health Gauge AI-based Wearable Device; Willing and cognitively able to sign informed consent Interstitial lung disease, chronic obstructive pulmonary disease, pulmonary hypertension, or a healthy control Exclusion Criteria: Pregnancy; History of active (clinically significant) skin disorders; History of allergic response to plastic materials; Subjects with electronic implants of any kind (e.g. pacemaker); Broken, damaged or irritated skin or rashes near the sensor application sites; Subjects who are physically or cognitively unable to normally perform activities of daily living, assessed at the discretion of the investigator. Exclusion Criteria for healthy control only: An active medical conditions for which they are on chronic treatment with drugs; Shortness of breath (any sort); Chronic cough; Fatigue or difficulty sleeping.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Device: Health Gauge AI-Based Wearable Device - Model: Phoenix

    Arm Description

    Outcomes

    Primary Outcome Measures

    Length of time wearing device
    Total length of time participant wears device

    Secondary Outcome Measures

    Prediction of respiratory exacerbations- Number of emergency room visits or hospitalizations
    Explore the possibility to predict exacerbations/flares up of the respiratory condition of the patients
    Adverse Events
    Number of adverse events

    Full Information

    First Posted
    March 27, 2023
    Last Updated
    August 1, 2023
    Sponsor
    University of Alberta
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05827302
    Brief Title
    Integrating ePReBMs From Phoenix in Respiratory Diseases
    Official Title
    Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From the Health Gauge Phoenix Smart Watch in Respiratory Diseases
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2023 (Anticipated)
    Primary Completion Date
    April 2028 (Anticipated)
    Study Completion Date
    April 2028 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Alberta

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Participants with respiratory disease experience often a worsening of their condition, with increasing symptoms such as cough and shortness of breath. This worsening, often called exacerbation or flare up, impacts on the life of the participants, since they become limited in their daily activities. Healthcare is still based today on limited times for clinical appointments to perform investigations and to meet with specialists/clinicians. Very often, these evaluations do not reflect the way the disease is limiting the patient's life. Wearable devices offer the opportunity to collect data on physical activities and important clinical parameters (such as how the patient is active or just staying in bed during the day), on a daily basis. The HG Phoenix AI- based Smart Watch produced by Health Gauge, an Albertan company based in Edmonton, has the potential to measure heart rate, heart rate variability, blood pressure, pulse wave velocity, respiratory rate, temperature, arterial saturation, sleep pattern (deep, light sleep, awake time), duration and time, daily physical activities (site count and distance) and calories burnt in a simple and non-invasive fashion. Ideally, these parameters could be monitored and recorded 24 hours per 7 days per week. This study aims to demonstrate that this device can be used for a long time at home and it is comfortable to use for the participants, that it is not dangerous and, possibly, that it can help to identify exacerbations before the currently available investigations.
    Detailed Description
    Participants will be asked to wear the Health Gauge AI-based Wearable Device for at least 8 hours per day (ideally 24 hours), 3 days per week, for 6 months. The following data will be continuously collected from the wearable device: heart rate, blood pressure, pulse wave velocity, respiratory rate, temperature, arterial saturation, sleep patterns, daily physical activities (step count and distance), and calories burnt. Clinical data including demographics, radiographic, cardiac and lung functioning, diagnosis, and comorbidities will be collected from the participant's electronic medical record at baseline, 3 months, and 6 months. Quality of life questionnaires (Saint George Respiratory Questionnaire, Medical Research Council Dyspnea Score, and EQ5-DL) will be completed by the participant through the Zamplo digital app at baseline, 3 and 6-month time points. A questionnaire on participant experience will also be administered at the 3 and 6-month time points. Participants will be called monthly to assess patient-reported compliance with the wearable device, and adverse events (including emergency room visits and hospitalizations).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pulmonary Hypertension, COPD, Interstitial Lung Disease, Healthy Volunteers

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Model Description
    The study will compare healthy controls to those with respiratory disease. Both groups will be wearing the watch and completing the same questionnaires
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    40 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Device: Health Gauge AI-Based Wearable Device - Model: Phoenix
    Arm Type
    Experimental
    Intervention Type
    Device
    Intervention Name(s)
    Health Gauge AI-Based Wearable Device - Model: Phoenix
    Intervention Description
    Wearable device
    Primary Outcome Measure Information:
    Title
    Length of time wearing device
    Description
    Total length of time participant wears device
    Time Frame
    6 months
    Secondary Outcome Measure Information:
    Title
    Prediction of respiratory exacerbations- Number of emergency room visits or hospitalizations
    Description
    Explore the possibility to predict exacerbations/flares up of the respiratory condition of the patients
    Time Frame
    6 months
    Title
    Adverse Events
    Description
    Number of adverse events
    Time Frame
    6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Male or female volunteers, at least 18 years of age at the time of screening visit; Fluent in English and able to follow the instructions to use the Health Gauge AI-based Wearable Device; Willing and cognitively able to sign informed consent Interstitial lung disease, chronic obstructive pulmonary disease, pulmonary hypertension, or a healthy control Exclusion Criteria: Pregnancy; History of active (clinically significant) skin disorders; History of allergic response to plastic materials; Subjects with electronic implants of any kind (e.g. pacemaker); Broken, damaged or irritated skin or rashes near the sensor application sites; Subjects who are physically or cognitively unable to normally perform activities of daily living, assessed at the discretion of the investigator. Exclusion Criteria for healthy control only: An active medical conditions for which they are on chronic treatment with drugs; Shortness of breath (any sort); Chronic cough; Fatigue or difficulty sleeping.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Breanne Stewart
    Phone
    7809748606
    Email
    breanne1@ualberta.ca

    12. IPD Sharing Statement

    Learn more about this trial

    Integrating ePReBMs From Phoenix in Respiratory Diseases

    We'll reach out to this number within 24 hrs